Qilu Pharmaceutical (hainan) Co Ltd

Qilu Pharmaceutical (Hainan) Co., Ltd. is a Chinese pharmaceutical manufacturer established in 2005 and headquartered in Haikou, Hainan province. It is a subsidiary of the much larger, privately held Qilu Pharmaceutical Co., Ltd., which was founded in 1958. The Hainan subsidiary employs over 500 people and was established as an "export pharmaceutics production base" for the parent company. The parent, Qilu Pharmaceutical Group, is one of China's largest pharmaceutical companies, with over 38,000 employees globally and reported revenue of approximately $5.6 billion USD in 2022.

As an operating company, Qilu Pharmaceutical (Hainan) manufactures and develops a range of pharmaceutical products. It specializes in oncological products, particularly lyophilized powder for injections. Its broader business scope includes chemical and antibiotic Active Pharmaceutical Ingredients (APIs) and their preparations, biochemical drugs, and biological products, with a focus on areas like cardiovascular treatments. The parent company is a vertically integrated firm with a wide portfolio of over 300 products, including anti-neoplastics, anti-infectives, and anti-emetics, which it sells in over 110 countries.

The company's patent litigation posture is that of a generic drug manufacturer being challenged by a brand-name drugmaker. The single tracked case is a defensive one, where Qilu Pharmaceutical (Hainan) is the defendant, a typical stance for an operating company in the pharmaceutical industry. The case was filed in the US District Court for the District of New Jersey, a common venue for such disputes.

The notable tracked case is Takeda Pharmaceutical Co Ltd v. Qilu Pharmaceutical (hainan) Co Ltd, filed in April 2026. This is a patent infringement lawsuit initiated under the Hatch-Waxman Act, arising from Qilu's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration. Takeda alleges that Qilu's proposed generic version of the antiviral drug Livtencity® (maribavir) infringes on several of its patents.